Search research articles
Contact Us
Filters
Showing results (31-40 of 52) with videos related to
Page
of 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2018
Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer
Alicia K Morgans, Yu-Hui Chen, Christopher J Sweeney, et al.
European Urology Oncology
|
December 28, 2023
PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy
Petros Grivas, Vadim S Koshkin, Xiangying Chu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 23, 2021
Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancer
Ritesh K Aggarwal, Rebecca A Luchtel, Venkata Machha, et al.
European Urology Oncology
|
April 17, 2025
Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trial
Daniel Sentana-Lledo, Xiangying Chu, Charles J Ryan, et al.
Cancer Discovery
|
May 3, 2020
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System
Vikas Mehta, Sanjay Goel, Rafi Kabarriti, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
April 14, 2019
Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases
Liwei Jia, Maria I Carlo, Hina Khan, et al.
The Journal of Clinical Investigation
|
April 23, 2024
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles
Pedro Barata, Shuchi Gulati, Andrew Elliott, et al.
British Journal of Cancer
|
November 11, 2023
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN
John Shen, Simon Chowdhury, Neeraj Agarwal, et al.
JNCI Cancer Spectrum
|
June 3, 2022
The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer
Neil J Shah, Vaibhav G Patel, Xiaobo Zhong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 16, 2022
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Chung-Han Lee, Robert Motzer, Hamid Emamekhoo, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 52) with videos related to
Sort By:
Page
of 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2018
Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer
Alicia K Morgans, Yu-Hui Chen, Christopher J Sweeney, et al.
European Urology Oncology
|
December 28, 2023
PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy
Petros Grivas, Vadim S Koshkin, Xiangying Chu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 23, 2021
Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancer
Ritesh K Aggarwal, Rebecca A Luchtel, Venkata Machha, et al.
European Urology Oncology
|
April 17, 2025
Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trial
Daniel Sentana-Lledo, Xiangying Chu, Charles J Ryan, et al.
Cancer Discovery
|
May 3, 2020
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System
Vikas Mehta, Sanjay Goel, Rafi Kabarriti, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
April 14, 2019
Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases
Liwei Jia, Maria I Carlo, Hina Khan, et al.
The Journal of Clinical Investigation
|
April 23, 2024
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles
Pedro Barata, Shuchi Gulati, Andrew Elliott, et al.
British Journal of Cancer
|
November 11, 2023
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN
John Shen, Simon Chowdhury, Neeraj Agarwal, et al.
JNCI Cancer Spectrum
|
June 3, 2022
The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer
Neil J Shah, Vaibhav G Patel, Xiaobo Zhong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 16, 2022
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Chung-Han Lee, Robert Motzer, Hamid Emamekhoo, et al.
Page
of 6